

Premenstrual syndrome and premenstrual dysphoric disorder: guidelines for management

Meir Steiner, MD, PhD

Departments of Psychiatry and Behavioural Neurosciences, and of Obstetrics and Gynecology, McMaster University, and Father Sean O'Sullivan Research Centre, St. Joseph's Hospital, Hamilton, Ont.

The inclusion of research diagnostic criteria for premenstrual dysphoric disorder (PMDD) in the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition, recognizes the fact that some women have extremely distressing emotional and behavioural symptoms premenstrually. PMDD can be differentiated from premenstrual syndrome (PMS), which presents with milder physical symptoms, headache, and more minor mood changes. In addition, PMDD can be differentiated from premenstrual magnification of physical or psychological symptoms of a concurrent psychiatric or medical disorder. As many as 75% of women with regular menstrual cycles experience some symptoms of PMS, according to epidemiologic surveys. PMDD is much less common; it affects only 3% to 8% of women in this group. The etiology of PMDD is largely unknown, but the current consensus is that normal ovarian function (rather than hormone imbalance) is the cyclical trigger for PMDD-related biochemical events within the central nervous system and other target organs. The serotonergic system is in a close reciprocal relation with the gonadal hormones and has been identified as the most plausible target for interventions. Thus, beyond conservative treatment options such as lifestyle and stress management, other non-antidepressant treatments, or the more extreme interventions that eliminate ovulation altogether, selective serotonin reuptake inhibitors (SSRIs) are emerging as the most effective treatment option. Results from several randomized, placebo-controlled trials in women with PMDD have clearly demonstrated that SSRIs have excellent efficacy and minimal side effects. More recently, several preliminary studies indicate that intermittent (premenstrual only) treatment with selective SSRIs is equally effective in these women and, thus, may offer an attractive treatment option for a disorder that is itself intermittent.

L'inclusion de critères diagnostics de recherche pour le trouble dysphorique prémenstruel (TDPM) dans le *Manuel diagnostique et statistique des troubles mentaux*, 4^e édition, reconnaît que certaines femmes ont, avant les menstruations, des symptômes émotionnels et comportementaux qui sont cause d'une détresse extrême. Il est possible de distinguer le TDPM du syndrome prémenstruel (SPM), lequel présente des symptômes physiques plus légers, des maux de tête et des changements d'humeur moins marqués. On peut aussi distinguer le TDPM de l'amplification prémenstruelle des symptômes physiques ou psychologiques d'un trouble psychiatrique ou médical simultané. Les enquêtes épidémiologiques indiquent que jusqu'à 75 p. 100 des femmes qui ont un cycle menstruel régulier ont des symptômes de SPM. Le TDPM est beaucoup moins fréquent : il atteint seulement de 3 p. 100 à 8 p. 100 des femmes de ce groupe. L'étiologie du TDPM est en grande partie inconnue, mais on s'entend généralement pour dire que la fonction ovarienne

Correspondence to: Dr. Meir Steiner, St. Joseph's Hospital, 50 Charlton Ave. East, Hamilton ON L8N 4A8; fax 905 521-6098; mst@fhs.mcmaster.ca

Medical subject headings: clinical protocols; diagnosis, differential; premenstrual syndrome; serotonin; serotonin uptake inhibitors

J Psychiatry Neurosci 2000;25(5):459-68.

Submitted Mar. 2, 2000

Revised Aug. 15, 2000

Accepted Sept. 18, 2000

© 2000 Canadian Medical Association

normale (plutôt qu'un déséquilibre hormonal) constitue le facteur de déclenchement cyclique d'événements biochimiques liés au TDPM dans le système nerveux central et d'autres organes cibles. Le système sérotoninergique fonctionne dans une relation de réciprocité étroite avec les hormones gonadiques et est considéré comme la cible la plus plausible d'interventions. Ainsi, outre des possibilités de traitement conservateur (modifications du style de vie et la gestion du stress, autres traitements sans antidépresseur ou interventions plus extrêmes éliminant complètement l'ovulation), les inhibiteurs spécifiques du recaptage de la sérotonine (ISRS) semblent constituer le traitement le plus efficace. Les résultats de plusieurs études randomisées et contrôlées par placebo réalisées chez des femmes atteintes de TDPM ont démontré clairement que les ISRS sont très efficaces et ont des effets secondaires minimes. Plusieurs études préliminaires récentes indiquent qu'un traitement intermittent (préménstruel seulement) au moyen des ISRS est tout aussi efficace chez ces femmes et peut ainsi offrir une possibilité intéressante de traitement d'un trouble qui est lui-même intermittent.

Epidemiologic surveys have estimated that as many as 75% of women of reproductive age experience some symptoms attributed to the premenstrual phase of the menstrual cycle.¹ More than 100 physical and psychological symptoms have been reported to occur premenstrually.² Most women are able to manage these symptoms through lifestyle changes and conservative therapies.

Premenstrual symptoms are often classified under the generic term "premenstrual syndrome" (PMS), which is listed in the *International Statistical Classification of Diseases and Related Health Problems*, 10th revision (ICD-10) under disorders of the genitourinary system. The symptoms included are menstrual migraine, menstrual molimen and premenstrual tension not otherwise specified.³ Approximately 3% to 8% of women of reproductive age report much more severe premenstrual symptoms of irritability, tension, dysphoria and lability of mood, which seriously interfere with their lifestyle and relationships.^{1,4-8} Without relief from these symptoms, a woman's functioning in the home, in social situations and at work can be substantially impaired each month, often over a span of many years.^{5,9,10} This cluster of primarily emotional and behavioural symptoms is so disruptive that a series of research diagnostic criteria for what is now called "premenstrual dysphoric disorder" (PMDD) have been developed and published in the 3rd revised and 4th editions of the *Diagnostic and Statistical Manual of Mental Disorders* (DSM-III-R and DSM-IV).^{11,12} Women who meet the diagnostic criteria for PMDD do not usually respond to conservative and conventional interventions and often seek the expertise of a health professional.

Etiology

The etiology of severe PMS and PMDD is largely unknown, but the current consensus seems to be that normal ovarian function (rather than hormone imbal-

ance) is the cyclical trigger for premenstrual-related biochemical events within the central nervous system and other target organs.^{13,14} That PMS and PMDD are biological (rather than psychological or psychosocial) phenomena is primarily underscored by recent, convincing evidence of the heritability of premenstrual symptoms¹⁵ and the elimination of premenstrual complaints with suppression of ovarian cyclicity¹⁶ or surgical menopause.^{17,18} This viewpoint encourages investigation of the neuroendocrine-modulated central neurotransmitters and the role of the hypothalamic-pituitary-gonadal (HPG) axis in PMDD.

Increasing evidence suggests that, of all the neurotransmitters studied to date, serotonin (5-HT) may be important in the pathogenesis of PMDD.¹⁹⁻²¹ PMDD also shares many of the features of other mood and anxiety disorders that have been linked to serotonergic dysfunction.²²⁻²⁴ In addition, reduction in brain 5-HT neurotransmission is thought to lead to poor impulse control, depressed mood, irritability and increased carbohydrate craving — all mood and behavioural symptoms associated with PMDD.²⁵ Animal studies have established reciprocity between fluctuations in ovarian steroid levels and serotonergic function, showing that estrogen and progesterone influence central serotonergic neuronal activity. In the hypothalamus, estrogen induces a diurnal fluctuation in 5-HT,²⁶ whereas progesterone increases the turnover rate of 5-HT.²⁷ Several challenge tests have also suggested abnormal 5-HT function in women with premenstrual dysphoria. A blunted growth hormone and cortisol response to tryptophan²⁸ as well as a blunted or delayed prolactin response to fenfluramine and buspirone challenges have been reported by most²⁹⁻³¹ but not all³² investigators. These studies imply, at least in part, a recurrent, cyclic 5-HT dysfunction in women with premenstrual mood changes.

Taken together, most research indicates that women with PMDD may be behaviourally or biochemically sub- or supersensitive to biological challenges of the serotonergic system. It is not yet clear whether these women present with a trait or state marker of PMDD.

Screening and diagnosis

There are no objective diagnostic tests for PMS and PMDD; therefore, a complete medical and psychiatric history must be elicited. Screening should also include a complete review of physical systems and medical disorders, and a detailed review of heritable disorders, including psychiatric disorders, in the patient's family. Since the symptoms of anemia and thyroid disease often mimic those of PMS or PMDD, the patient should undergo laboratory investigations if she is considered at risk for these conditions. Before making a diagnosis of PMS or PMDD, concurrent major mental disorders, personality disorders and medical conditions must be excluded.

Prospective daily rating of symptoms is essential in making a diagnosis. The patient should chart her symptoms for at least 2 consecutive symptomatic menstrual cycles. To date, there is no consensus among investigators as to the best instruments for prospectively confirming the diagnosis of PMDD, although there are now several scales and calendars to facilitate this.³³⁻³⁶ A patient in whom PMDD is suspected should be assessed at least once during each cycle phase to ensure that she subjectively endorses phase-appropriate mood symptoms, corroborating her daily charting (none or minimal during the follicular phase; lifestyle-impairing during the luteal phase).

The psychiatric, medical and psychosocial screens, together with verification of the timing of symptoms, enable the clinician to make a diagnosis. Possible diagnoses after screening include: 1) PMS or PMDD; 2) another psychiatric or medical illness only; 3) PMS or PMDD coexisting with another illness; 4) premenstrual exacerbation/magnification of an underlying psychiatric or medical illness; or, 5) no diagnosis (situational, psychosocial stressors).³⁷

To meet the criteria for PMDD, women must not only show symptoms by charting daily for a minimum of 2 consecutive, symptomatic menstrual cycles, but their chief complaints must also include 1 of the 4 core symptoms (irritability, tension, dysphoria, lability of mood) and at least 5 of the 11 total symptoms (Table 1). The

symptoms must have occurred within most menstrual cycles during the last year and must have interfered with social or occupational roles. It has been suggested that there should be at least a 30% change (worsening) in symptoms between the follicular and the luteal phase to make a diagnosis of PMDD, regardless of the daily rating scale that is being used.^{36,38,39} The charting must demonstrate clear worsening of symptoms premenstrually, and remission within a few days after menstruation begins, commonly referred to as "on-offness" of symptoms. This is in stark contrast with the ICD-10 criteria, which require only 1 symptom for a diagnosis of PMS. Unlike the criteria for PMDD, the presence of an emotional symptom is not required for the diagnosis of PMS, nor is there a requirement for prospective confirmation or for functional impairment.³

A woman may have a psychiatric or medical disorder as well as PMS or PMDD. In such cases, the premenstrual symptoms are distinct from the other disorder, and arise during the luteal phase and remit during the follicular phase. Patients can also demonstrate premenstrual exacerbation or magnification of an underlying psychiatric or medical illness. Dysphoria and fatigue, in particular, are symptoms that PMS and PMDD share with various medical and psychiatric disorders. Other symptoms shared by PMS and PMDD and psychiatric illnesses are panic, anxiety, bulimia and substance abuse. In premenstrual exacerbation or magnification of a medical or psychiatric illness, the symptoms persist

Table 1: Criteria for premenstrual dysphoric disorder (PMDD, modified from the *Diagnostic and Statistical Manual of Mental Disorders*, 4th edition¹²)

A	Symptoms must occur during the week before menses and remit a few days after onset of menses. Five of the following symptoms must be present and at least one must be (1), (2), (3), or (4). 1 Depressed mood or dysphoria 2 Anxiety or tension 3 Affective lability 4 Irritability 5 Decreased interest in usual activities 6 Concentration difficulties 7 Marked lack of energy 8 Marked change in appetite, overeating, or food cravings 9 Hypersomnia or insomnia 10 Feeling overwhelmed 11 Other physical symptoms, e.g., breast tenderness, bloating
B	Symptoms must interfere with work, school, usual activities or relationships
C	Symptoms must not merely be an exacerbation of another disorder
D	Criteria A, B, and C must be confirmed by prospective daily ratings for at least 2 consecutive symptomatic menstrual cycles

throughout the menstrual cycle but worsen premenstrually. Some women have continuous symptoms (as in dysthymia) or cyclical symptoms that do not match the phases of their menstrual cycle (as in cyclothymia). Women who do not meet the criteria for any diagnosis may subjectively sense disruptive symptoms as a result of psychosocial stressors and likely still benefit from charting and conservative interventions.

Treatment

A wide range of therapeutic interventions have been tested in the treatment of premenstrual symptoms. For women who do not meet criteria for PMDD or other physical and psychological disorders, conservative treatments are appropriate, and nonpharmacologic management should be encouraged. Unfortunately, there have been few randomized controlled trials to determine the efficacy of these more conservative interventions (Table 2); however, there is some evidence that these patients may best respond to individual or group cognitive-behavioural psychotherapy in combination with lifestyle changes. Recommended dietary changes (especially during the luteal phase) should include reducing or limiting intake of tobacco, chocolate, caffeine and alcohol. Some women report improvement as a result of eating small, frequent meals high in complex carbohydrates, as well as taking vitamins and minerals in moderation. A recent study identified the efficacy of a specially formulated carbohydrate-rich beverage compared with placebo.⁴⁰ Patients should be encouraged to decrease excess sodium in the diet when edema or fluid retention occurs and, if possible, to reduce their body mass index to less than 25 kg/m².⁴¹ Regular exercise is important^{42,43} and particularly effective when combined with the regular practice of stress manage-

ment techniques. Patients should also be taught to review their own monthly diaries and identify triggers that exacerbate symptoms.

Most nonpharmacologic interventions that have been proven efficacious require a series of interventions. Cognitive-behavioural therapy in the form of 12 weekly individual sessions significantly improved symptoms and functional impairment in women with PMS randomly assigned to immediate treatment, compared with those in the waiting-list control group.⁴⁴ Ear, hand and foot reflexology administered once weekly for 8 weeks by a trained reflexologist significantly decreased premenstrual symptoms in women who received treatment compared with those who received "sham" reflexology.⁴⁵

Of the low-risk pharmacologic interventions that have been studied under controlled conditions (Table 3), calcium carbonate (1000 to 1200 mg daily) significantly improved affect and alleviated water retention, food cravings and pain after 3 treatment cycles.^{46,47} Magnesium supplementation (200 mg or 360 mg daily during the luteal phase) significantly reduced premenstrual fluid retention after 2 cycles of treatment.^{48,49} There have been enough studies of vitamin B6 to allow for a systematic review, which concluded that doses of up to 100 mg daily are likely to be of moderate benefit in treating premenstrual symptoms and depression.⁵⁰ Additional treatments that have demonstrated efficacy include nutritional supplements^{51,52} and daily administration of vitamin E.⁵³ A systematic review of evening primrose oil concluded that this intervention was ineffective for this disorder.⁵⁴ Mefenamic acid given premenstrually alleviated fatigue, headache, aches and pains, and improved mood,⁵⁵ whereas premenstrual administration of naproxen reduced pain in one study,⁵⁶ and daily naproxen administration improved menstrual migraine in another.⁵⁷ Daily or luteal-phase administration of spironolactone appears efficacious for somatic and physical symptoms, including weight gain and bloatedness.⁵⁸⁻⁶⁰ For mastalgia, bromocriptine (1.25 to 7.5

Table 2: Conservative interventions to treat PMS or PMDD

Charting	Daily charting of symptoms
Diet	Reduction or elimination, especially in the luteal phase, of salt, chocolate, caffeine and alcohol; small, frequent meals high in complex carbohydrate; vitamins and minerals in moderation
Exercise	Moderate, regular, aerobic exercise
Stress reduction	Stress management courses or counselling, if necessary, or both
Relaxation	Relaxation courses or audiotapes
Relationship	Assertiveness course or marital counselling, if necessary, or both
Self-help groups	If available
Education	Self-help books

Table 3: Low-risk pharmacological interventions supported by the evidence

Supplement	Dosage
Vitamin B6	100 mg daily
Calcium	1000 to 1200 mg daily
Magnesium ion	200 mg daily or 360 mg daily (14 days before menses)
Vitamin E	400 IU daily

mg daily during the luteal phase) was helpful in 10 of 14 randomized trials.⁶¹

The pharmacological approaches to PMDD and severe PMS include psychotropic medications and hormonal interventions. The newer antidepressants in particular, including many of the selective serotonin reuptake inhibitors (SSRIs)^{9,62-77} as well as clomipramine^{78,79} and L-tryptophan,⁸⁰ have demonstrated excellent efficacy and minimal side effects in women with severe PMS and PMDD in whom conservative treatment has failed (Table 4). There is increasing evidence that intermittent low-dose SSRI treatment significantly improves both psychological and physical premenstrual symptoms within the first few cycles of treatment.^{72-77,79} Intermittent treatment typically consists of starting medications 14 days before menstruation starts and continuing daily treatment until menstruation or shortly thereafter. In spite of considerable differences in chemical structure, all SSRIs appear to be effective for PMDD and PMS. SSRI treatment is not contraindicated for women taking oral contraceptives.

The anxiolytics alprazolam⁸¹⁻⁸³ and buspirone⁸⁴ have also demonstrated efficacy in most trials; however, the magnitude of the therapeutic effect is less than that of SSRIs, while the side effect profile and potential for dependence are cause for caution.

The second line of pharmacological treatment includes hormonal agents. In particular, gonadotropin-releasing hormone (GnRH) agonists can temporarily suppress the menstrual cycle (often called "medical ovariectomy" or "medical menopause"). In clinical trials, GnRH agonists have proven very successful in relieving physical symptoms (Table 4). Unfortunately, the long-term use of GnRH agonists is limited by the occurrence of side effects that mimic menopause and the potential for hypo-estrogenism and osteoporosis.

Preliminary evidence suggests that "add-back" therapy with low-dose estrogen and progesterone replacement therapy may prevent some of these side effects.⁸⁵ Intranasal buserelin^{86,87} or intramuscular leuprolide^{88,89} are the most appropriate GnRH treatments for clinical use. In clinical trials, danazol has also been effective,⁹⁰⁻⁹⁴ most recently in the treatment of premenstrual mastalgia.⁹⁵ The final line of treatment is ovariectomy. Two open studies have demonstrated the effectiveness of ovariectomy in the complete relief of severe premenstrual symptoms.^{17,18}

Oral contraceptives suppress ovulation while maintaining menstruation due to periodic withdrawal. The one clinical trial testing oral contraceptives for the treatment of PMS was a negative study,⁹⁶ which supported the conclusions of other less rigorous research. Until additional research has been done, oral contraceptives are not recommended for the treatment of PMS or PMDD.

Women who manifest severe physical symptoms or a psychiatric disorder with premenstrual magnification should be treated for their primary condition. Premenstrual symptoms usually remit considerably with successful treatment of the primary condition, and residual symptoms can be treated as indicated.

SSRIs and reproduction

Side effects attributable to SSRIs are usually mild and transient.⁹⁷ We have recently reported that the length of the menstrual cycle may be shortened in women receiving fluoxetine (60 mg daily) compared with women receiving fluoxetine (20 mg daily) or placebo; however, the significance of this finding is as yet unknown.⁹⁸ Perhaps the most troublesome SSRI side effect for women is sexual dysfunction, defined as "normal libido and arousal with delayed or absent orgasm." This side

Table 4: Pharmacological interventions to treat PMS and PMDD that are supported by evidence

Drug class	Drug	Dosage
Antidepressants	Fluoxetine	20 mg/d, every day or during luteal phase only
	Sertraline	50–150 mg/d, every day or during luteal phase only
	Paroxetine	10–30 mg/d, every day or during luteal phase only
	Citalopram	5–20 mg/d, every day or during luteal phase only
	Clomipramine	25–75 mg/d, every day or during luteal phase only
Anxiolytics	Alprazolam	0.25–1.0 mg/tid, 6–14 days before menses
	Buspirone	25 mg/d, 12 days before menses
Ovulation suppressants (GnRH agonists)	Buserelin	400–900 mg/day (intranasal)
	Leuprolide	3.75–7.5 mg/mo (intramuscular injection)
	Danazol	200–400 mg/d, intermittent

effect can be reduced by reducing the dose, taking "drug holidays," substituting another agent or augmenting treatment with various agents.⁹⁹ Unfortunately, few clinical trials have included a systematic assessment of sexual function; therefore, the prevalence of anorgasmia as an SSRI side effect in women with PMDD is currently unknown. Clinicians should ask patients about sexual side effects.

The fact that all psychotropic medications diffuse readily across the placenta may raise concern regarding the use of these agents during pregnancy. Because knowledge about the risk of in utero exposure to psychotropic medications is incomplete, women should be counselled on the use of contraception while taking these medications. SSRIs have been shown to be relatively safe in first-trimester or late prenatal exposure.¹⁰⁰⁻¹⁰³ The largest amount of data regarding SSRI use in pregnancy involves fluoxetine and indicates that this drug is safe in pregnancy. A review of all published literature, which included outcomes of more than 1000 pregnancies in which the mother was taking fluoxetine, has concluded that in utero exposure to fluoxetine did not affect global IQ, language development or behavioural development in preschool-aged children.¹⁰⁴

Prognosis and outcome

To date, no single intervention has proven to be equal-

ly effective in treating *all* women with severe PMS or PMDD, although SSRIs have demonstrated tolerability and efficacy in more than 60% of patients studied.¹⁰⁵⁻¹⁰⁷

Patients should be assessed every 2 weeks (i.e., during both the follicular and luteal phases) within the first month of commencing therapy and instructed to continue to chart their symptoms daily. Dosage strategies vary; however, most recent investigations have demonstrated the efficacy of most therapeutic drugs at low dosages. If efficacy has not been attained after several increases in dosage, other treatment options should be considered. There is also evidence that response will be relatively immediate in women with PMS or PMDD; thus, if there is no change in symptoms within 2 to 3 menstrual cycles, an alternative therapy should be considered. Continued symptom charting helps to track efficacy, symptom response to changes in dosage, symptoms upon termination of therapy, and real versus perceived side effects. For example, women who report headaches or nausea as side effects are often surprised to see that they rated these symptoms as just as severe before commencing therapy.

Investigators have yet to reach a consensus on how to define efficacy. Clinically, the easiest way to define efficacy is by the reduction of luteal symptoms (that is, the luteal symptoms remit significantly or the difference between the follicular and luteal phases is less than 30%). It has become obvious that intervention alone




Fig. 1: Algorithm for diagnosing and treating premenstrual syndrome and premenstrual dysphoric disorder

cannot predict efficacy, and more consideration is now being given to psychiatric history as well as to family psychiatric history, especially to mood disorders in the families of women with PMDD.

There are 3 major concerns regarding the prognosis in severe PMS or PMDD: 1) the average age of onset is around 26 years, 2) there is evidence that symptoms gradually worsen over time, and 3) there is evidence that symptoms recur when treatment is halted.^{105,106} For these reasons, therapeutic goals must be set to ensure maximal safety and efficacy for the patient.

Diagnosis and treatment algorithm (Fig. 1)

The first step in assessing a patient who presents with PMS is to rule out other medical conditions or major psychiatric disorders and chart symptoms prospectively for at least 2 consecutive symptomatic cycles (Line 1, Consultation). The next step is to review the prospective charting for on-offness of symptoms, most troublesome symptoms, and the timing of symptoms with relation to the menstrual cycle (Line 2, Assessment). With this data in hand, the clinician can define the clustering of symptoms (Line 3, Symptom Profile) and work toward a differential diagnosis (Line 4). Once a differential diagnosis has been made, the clinician can begin to create a Treatment Plan (Line 5). The plan will vary, but should start with conservative therapies and move up the spectrum of evidence-based therapies as required. Women with a diagnosis of PMDD or PMS may be at risk of severe symptoms throughout their reproductive lifecycle. Therapeutic goals should be the cessation of symptoms, or their reduction to tolerable levels; if pharmacologic interventions are required, the emphasis should be on minimizing the dosage and side effects.

Conclusion

Most women of reproductive age experience premenstrual symptoms that can be physical or affective in nature. Approximately 5% of these women experience severe premenstrual symptoms that markedly influence work, social activities or relationships. Prospective charting of premenstrual symptoms for at least 2 menstrual cycles is required to facilitate an accurate diagnosis of this condition. While many women meet criteria for PMS or PMDD, others have premenstrual worsening of a pre-existing condition, or a continuous or inter-

mittent condition not related to the menstrual cycle.

Treatment of women with PMS or PMDD should begin with conservative and low-risk interventions, followed by prescribed pharmacological interventions. Low-dose SSRIs have demonstrated excellent efficacy with minimal side effects, and there is increasing evidence that intermittent treatment is as efficacious as continuous daily treatment. Second-line therapy consists of modification of the menstrual cycle and should be considered only after all other treatment options have failed.

Acknowledgement

The author wishes to acknowledge the assistance of Janice Rogers in the preparation of this manuscript.

References

1. Johnson SR, McChesney C, Bean JA. Epidemiology of premenstrual symptoms in a nonclinical sample. I. Prevalence, natural history and help-seeking behaviour. *J Reprod Med* 1988;33:340-6.
2. Budeiri DJ, Li Wan Po A, Dornan JC. Clinical trials of treatments of premenstrual syndrome: entry criteria and scales for measuring treatment outcomes. *Br J Obstet Gynaecol* 1994;101: 689-95.
3. World Health Organization. *International Statistical Classification of Diseases and Related Problems*, 10th revision (ICD-10). Geneva: WHO; 1992.
4. Rivera-Tovar AD, Frank E. Late luteal phase dysphoric disorder in young women. *Am J Psychiatry* 1990;147:1634-6.
5. Andersch B, Wendestam C, Hahn L, Ohman R. Premenstrual complaints. I. Prevalence of premenstrual symptoms in a Swedish urban population. *J Psychosom Obstet Gynaecol* 1986; 5:39-49.
6. Merikangas KR, Foeldenyi M, Angst J. The Zurich Study. XIX. Patterns of menstrual disturbances in the community: results of the Zurich Cohort Study. *Eur Arch Psychiatry Clin Neurosci* 1993;243:23-32.
7. Ramcharan S, Love EJ, Fick GH, Goldfien A. The epidemiology of premenstrual symptoms in a population based sample of 2650 urban women: attributable risk and risk factors. *J Clin Epidemiol* 1992;45:377-92.
8. Gehlert S, Hartlage S. A design for studying the DSM-IV research criteria of premenstrual dysphoric disorder. *J Psychosom Obstet Gynaecol* 1997;18:36-44.
9. Yonkers KA, Halbreich U, Freeman EW, Brown CS, Endicott J, Frank E, et al. Symptomatic improvement of premenstrual dysphoric disorder with sertraline treatment: a randomized controlled trial. *JAMA* 1997;278:983-8.
10. Johnson SR. The epidemiology and social impact of premenstrual symptoms. *Clin Obstet Gynecol* 1987;30:367-76.
11. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 3rd Edition, Revised. Washington: American Psychiatric Association; 1987. p. 367-9.
12. American Psychiatric Association. *Diagnostic and Statistical Manual of Mental Disorders*, 4th Edition. Washington: American Psychiatric Association; 1994. p. 715-8.
13. Roca CA, Schmidt PJ, Bloch M, Rubinow DR. Implications of

- endocrine studies of premenstrual syndrome. *Psychiatr Ann* 1996;26:576-80.
14. Rubinow DR, Schmidt PJ. The treatment of premenstrual syndrome — forward into the past. *N Engl J Med* 1995;332:1574-5.
 15. Kendler KS, Karkowski LM, Corey LA, Neale MC. Longitudinal population-based twin study of retrospectively reported premenstrual symptoms and lifetime major depression. *Am J Psychiatry* 1998;155:1234-40.
 16. Schmidt PJ, Nieman LK, Danaceau MA, Adams LF, Rubinow DR. Differential behavioural effects of gonadal steroids in women with and in those without premenstrual syndrome. *N Engl J Med* 1998;338:209-16.
 17. Casper RF, Hearn MT. The effect of hysterectomy and bilateral oophorectomy in women with severe premenstrual syndrome. *Am J Obstet Gynecol* 1990;162:105-9.
 18. Casson P, Hahn PM, Van Vugt DA, Reid RL. Lasting response to ovariectomy in severe intractable premenstrual syndrome. *Am J Obstet Gynecol* 1990;162:99-105.
 19. Rapkin AJ. The role of serotonin in premenstrual syndrome. *Clin Obstet Gynecol* 1992;35(3):629-36.
 20. Rojansky N, Halbreich U, Zander K, Barkai A, Goldstein S. Imipramine receptor binding and serotonin uptake in platelets of women with premenstrual changes. *Gynecol Obstet Invest* 1991;31:146-152.
 21. Steiner M, Lepage P, Dunn EJ. Serotonin and gender-specific psychiatric disorders. *Int J Psychiatr Clin Prac* 1997;1:3-13.
 22. Endicott J. The menstrual cycle and mood disorders. *J Affect Disord* 1993;29:193-200.
 23. Pearlstein TB, Frank E, Rivera-Tovar A, Thoft JS, Jacobs E, Mieczkowski TA. Prevalence of axis I and axis II disorders in women with late luteal phase dysphoric disorder. *J Affect Disord* 1990;20:129-34.
 24. Wurtman JJ. Depression and weight gain: the serotonin connection. *J Affect Disord* 1993;29:183-92.
 25. Meltzer HY. Serotonergic dysfunction in depression. *Br J Psychiatry* 1989;155 (Suppl 8):25-31.
 26. Cohen IR, Wise PM. Effects of estradiol on the diurnal rhythm of serotonin activity in microdissected brain areas of ovariectomized rats. *Endocrinology* 1988;122:2619-25.
 27. Ladisch W. Influence of progesterone on serotonin metabolism: a possible causal factor for mood changes. *Psychoneuroendocrinology* 1977;2:257-66.
 28. Bancroft J, Cook A, Davidson D, Bennie J, Goodwin G. Blunting of neuroendocrine responses to infusion of L-tryptophan in women with perimenstrual mood change. *Psychol Med* 1991;21:305-12.
 29. Yatham LN. Is 5HT-1a receptor subsensitivity a trait marker for late luteal phase dysphoric disorder? A pilot study. *Can J Psychiatry* 1993;38:662-4.
 30. FitzGerald M, Malone KM, Li S, Harrison WM, McBride PA, Endicott J, et al. Blunted serotonin response to fenfluramine challenge in premenstrual dysphoric disorder. *Am J Psychiatry* 1997;154:556-8.
 31. Steiner M, Yatham LN, Coote M, Wilkins A, Lepage P. Serotonergic dysfunction in women with pure premenstrual dysphoric disorder: is the fenfluramine challenge test still relevant? *Psychiatry Res* 1999;87:107-15.
 32. Bancroft J, Cook A. The neuroendocrine response to d-fenfluramine in women with premenstrual depression. *J Affect Disord* 1995;36:57-64.
 33. Reid RL. Premenstrual syndrome. *Curr Probl Obstet Gynecol Fertil* 1985;8:1-57.
 34. Mortola JF, Girton L, Beck L, Yen SS. Diagnosis of premenstrual syndrome by a simple, prospective, and reliable instrument: the calendar of premenstrual experiences. *Obstet Gynecol* 1990;76:302-7.
 35. Freeman EW, DeRubeis RJ, Rickels K. Reliability and validity of a daily diary for premenstrual syndrome. *Psychiatry Res* 1996;65:97-106.
 36. Steiner M, Streiner DL, Steinberg S, Stewart D, Carter D, Berger C, et al. The measurement of premenstrual mood symptoms. *J Affect Disord* 1999;53:269-73.
 37. Steiner M, Wilkins A. Diagnosis and assessment of premenstrual dysphoria. *Psychiatr Ann* 1996;26:571-5.
 38. National Institute of Mental Health. NIMH Premenstrual Syndrome Workshop Guidelines; April 14-15, 1983; Rockville, MD: National Institute of Mental Health.
 39. Steiner M, Yonkers KA. *Depression in Women*. London (UK): Martin Dunitz Publishers; 1998.
 40. Sayegh R, Schiff I, Wurtman J, Spiers P, McDermott J, Wurtman R. The effect of a carbohydrate-rich beverage on mood, appetite, and cognitive function in women with premenstrual syndrome. *Obstet Gynecol* 1995;86:520-8.
 41. Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. *JAMA* 1999;282:1523-9.
 42. Johnson WG, Carr-Nangle RE, Bergeron KC. Macronutrient intake, eating habits, and exercise as moderators of menstrual distress in healthy women. *Psychosom Med* 1995;57:324-30.
 43. Prior JC, Vigna V, Sciarretta D, Alojado N, Schulzer M. Conditioning exercise decreases premenstrual symptoms: a prospective, controlled 6-month trial. *Fertil Steril* 1987;47:402-8.
 44. Blake F, Salkovskis P, Gath D, Day A, Garrod A. Cognitive therapy for premenstrual syndrome: a controlled trial. *J Psychosom Res* 1998;45:307-18.
 45. Oleson T, Flocco W. Randomized controlled study of premenstrual symptoms treated with ear, hand and foot reflexology. *Obstet Gynecol* 1993;82:906-111.
 46. Thys-Jacobs S, Ceccarelli S, Bierman A, Weisman H, Cohen MA, Alvir J. Calcium supplementation in premenstrual syndrome: a randomized crossover trial. *J Gen Intern Med* 1989; 4:183-9.
 47. Thys-Jacobs S, Starkey P, Bernstein D, Tian J. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual symptoms. *Am J Obstet Gynecol* 1998;179:444-52.
 48. Walker AF, DeSouza MC, Vickers MF, Abeyasekera S, Collins ML, Trinca LA. Magnesium supplementation alleviates premenstrual symptoms of fluid retention. *J Womens Health* 1998;7:1157-65.
 49. Facchinetti F, Borella P, Sances G, Fioroni L, Nappi RE, Genazzani AR. Oral magnesium successfully relieves premenstrual mood changes. *Obstet Gynecol* 1991;78:177-81.
 50. Wyatt KM, Dimmock PW, Jones PW, O'Brien PMS. Efficacy of vitamin B6 in the treatment of premenstrual syndrome: systematic review. *BMJ* 1999;318:1375-81.
 51. London RS, Bradley L, Chiamori NY. Effect of a nutritional supplement on premenstrual symptomatology in women with premenstrual syndrome: a double-blind longitudinal study. *J Am Coll Nutr* 1991;10:494-9.
 52. Facchinetti F, Nappi RE, Sances MG, Neri I, Grandinetti G, Genazzani A. Effects of yeast-based dietary supplementation on premenstrual syndrome. A double-blind placebo-controlled study. *Gynecol Obstet Invest* 1997;43:120-4.
 53. London RS, Murphy L, Kitlowski KE, Reynolds MA. Efficacy of alpha-tocopherol in the treatment of premenstrual syndrome. *J Reprod Med* 1987;32:400-4.

54. Budeiri DJ, Li Wan Po A, Dornan JC. Is evening primrose oil of value in the treatment of premenstrual syndrome. *Control Clin Trials* 1996;17:60-8.
55. Mira M, McNeil D, Fraser IS, Vizzard J, Abraham S. Mefenamic acid in the treatment of premenstrual syndrome. *Obstet Gynecol* 1986;68:395-8.
56. Facchinetti F, Fioroni L, Sances G, Romano G, Nappi G, Genazzani AR. Naproxen sodium in the treatment of premenstrual syndromes. A placebo controlled study. *Gynecol Obstet Invest* 1989;28:205-8.
57. Sances G, Martignoni E, Fioroni L, Blandini F, Facchinetti F, Nappi G. Naproxen sodium in menstrual migraine prophylaxis: a double-blind placebo controlled study. *Headache* 1990;30:705-9.
58. O'Brien PMS, Craven D, Selby C, Symonds EM. Treatment of premenstrual syndrome by spironolactone. *Br J Obstet Gynaecol* 1979;86:142-7.
59. Vellacott ID, Shroff NE, Pearce MY, Stratford ME, Akbar FA. A double-blind, placebo-controlled evaluation of spironolactone in the premenstrual syndrome. *Curr Med Res Opin* 1987;10:450-6.
60. Wang M, Hammarback S, Lindhe B-A, Backstrom T. Treatment of premenstrual syndrome by spironolactone: a double-blind, placebo-controlled study. *Acta Obstet Gynecol Scand* 1995;74: 803-8.
61. Andersch B. Bromocriptine and premenstrual symptoms: a survey of double blind trials. *Obstet Gynecol Surv* 1983;38:643-6.
62. Stone AB, Pearlstein TB, Brown WA. Fluoxetine in the treatment of late luteal phase dysphoric disorder. *J Clin Psychiatry* 1991;52:290-3.
63. Wood SH, Mortola JF, Chan Y-F, Moossazadeh F, Yen SSC. Treatment of premenstrual syndrome with fluoxetine: a double-blind, placebo-controlled, crossover study. *Obstet Gynecol* 1992;80:339-44.
64. Menkes DB, Taghavi E, Mason PA, Spears GFS, Howard RC. Fluoxetine treatment of severe premenstrual syndrome. *BMJ* 1992;305:346-7.
65. Eriksson E, Hedberg MA, Andersch B, Sundblad C. The serotonin reuptake inhibitor paroxetine is superior to the noradrenaline reuptake inhibitor maprotiline in the treatment of premenstrual syndrome. *Neuropsychopharmacology* 1995;12:167-76.
66. Steiner M, Steinberg S, Stewart D, Carter D, Berger C, Reid R, et al. Fluoxetine in the treatment of premenstrual dysphoria. *N Engl J Med* 1995;332:1529-34.
67. Su T-P, Schmidt PJ, Danaceau MA, Tobin MB, Rosenstein DL, Murphy DL, et al. Fluoxetine in the treatment of premenstrual dysphoria. *Neuropsychopharmacology* 1997;16:346-56.
68. Pearlstein TB, Stone AB, Lund SA, Scheft H, Zlotnick C, Brown WA. Comparison of fluoxetine, bupropion, and placebo in the treatment of premenstrual dysphoric disorder. *J Clin Psychopharmacol* 1997;17:261-6.
69. Ozeren S, Corakci A, Yucesoy I, Mercan R, Erhan G. Fluoxetine in the treatment of premenstrual syndrome. *Eur J Obstet Gynecol Reprod Biol* 1997;73:167-70.
70. Diegoli MSC, da Fonseca AM, Diegoli CA, Pinotti JA. A double-blind trial of four medications to treat severe premenstrual syndrome. *Int J Gynaecol Obstet* 1998;62:63-7.
71. Freeman EW, Rickels K, Sodheimer SJ, Polansky M. Differential response to antidepressants in women with premenstrual syndrome/premenstrual dysphoric disorder: a randomized controlled trial. *Arch Gen Psychiatry* 1999;56:932-9.
72. Halbreich U, Smoller JW. Intermittent luteal phase sertraline treatment of dysphoric premenstrual syndrome. *J Clin Psychiatry* 1997;58:399-402.
73. Steiner M, Korzekwa M, Lamont J, Wilkins A. Intermittent fluoxetine dosing in the treatment of women with premenstrual dysphoria. *Psychopharmacol Bull* 1997;33:771-4.
74. Young SA, Hurt PH, Benedek DM, Howard RS. Treatment of premenstrual dysphoric disorder with sertraline during the luteal phase: a randomized, double-blind, placebo-controlled crossover trial. *J Clin Psychiatry* 1998;59:76-80.
75. Wikander I, Sundblad C, Andersch B, Dagnell I, Zylberstein D, Bengtsson F, et al. Citalopram in premenstrual dysphoria: is intermittent treatment during luteal phases more effective than continuous medication throughout the menstrual cycle? *J Clin Psychopharmacol* 1998;18:390-8.
76. Jermain DM, Preece CK, Sykes RL, Kuehl TJ, Sulak PJ. Luteal phase sertraline treatment for premenstrual dysphoric disorder. Results of a double-blind, placebo-controlled, crossover study. *Arch Fam Med* 1999;8:328-32.
77. Freeman EW, Rickels K, Arredondo F, Kao LC, Pollack SE, Sondheimer SJ. Full or half-cycle treatment of severe premenstrual syndrome with a serotonergic antidepressant. *J Clin Psychopharmacol* 1999;19:3-8.
78. Sundblad C, Modigh K, Andersch B, Eriksson E. Clomipramine effectively reduces premenstrual irritability and dysphoria: a placebo controlled trial. *Acta Psychiatr Scand* 1992;85:39-47.
79. Sundblad C, Hedberg MA, Eriksson E. Clomipramine administered during the luteal phase reduces the symptoms of premenstrual syndrome: a placebo-controlled trial. *Neuropsychopharmacology* 1993;9:133-45.
80. Steinberg S, Annable L, Young SN, Liyanage N. A placebo controlled clinical trial of L-tryptophan in premenstrual dysphoria. *Biol Psychiatry* 1999;45:313-20.
81. Smith S, Rinehart JS, Ruddock VE, Schiff I. Treatment of premenstrual syndrome with alprazolam: results of a double-blind, placebo-controlled, randomized crossover clinical trial. *Obstet Gynecol* 1987;70:37-43.
82. Berger CP, Presser B. Alprazolam in the treatment of two subsamples of patients with late luteal phase dysphoric disorder: a double-blind, placebo-controlled crossover study. *Obstet Gynecol* 1994;84:379-85.
83. Harrison WM, Endicott J, Nee J. Treatment of premenstrual dysphoria with alprazolam. A controlled study. *Arch Gen Psychiatry* 1990;47:270-5.
84. Rickels K, Freeman E, Sondheimer S. Buspirone in treatment of premenstrual syndrome. *Lancet* 1989;1:777.
85. Mortola JF, Girton L, Fischer U. Successful treatment of severe premenstrual syndrome by combined use of gonadotrophin-releasing hormone agonist and estrogen/progestin. *J Clin Endocrinol Metab* 1991;72:252A-252F.
86. Hammarback S, Backstrom T. Induced anovulation as treatment of premenstrual tension syndrome. A double-blind crossover study with GnRH-agonist versus placebo. *Acta Obstet Gynecol Scand* 1988;67:159-66.
87. Hussain SY, Massil JH, Matta WH, Shaw RW, O'Brien PM. Buserelin in premenstrual syndrome. *Gynecol Endocrinol* 1992;6:57-64.
88. Brown CS, Ling FW, Andersen RN, Farmer RG, Arheart KL. Efficacy of depot leuprolide in premenstrual syndrome: effect of symptom severity and type in a controlled trial. *Obstet Gynecol* 1994;84:779-86.
89. Helvacioğlu A, Yeoman RR, Hazelton JM, Aksel S. Premenstrual syndrome and related hormonal changes. Long-acting gonadotropin releasing hormone agonist treatment. *J Reprod Med* 1993;38:864-70.
90. Watts JF, Butt WR, Logan Edwards RL. A clinical trial using danazol for the treatment of premenstrual tension. *Br J Obstet*

- Gynaecol* 1987;94:30-4.
91. Hahn PM, Van Vugt DA, Reid RL. A randomized, placebo-controlled, crossover trial of danazol for the treatment of premenstrual syndrome. *Psychoneuroendocrinology* 1995;20:193-209.
 92. Deeny M, Hawthorn R, McKay-Hart D. Low dose danazol in the treatment of the premenstrual syndrome. *Postgrad Med J* 1991;67:450-4.
 93. Gilmore DH, Hawthorn RJ, Hart DM. Danol for premenstrual syndrome: a preliminary report of a placebo-controlled double-blind study. *J Int Med Res* 1985;13:129-30.
 94. Sarno AP, Jr., Miller EJ, Jr., Lundblad EG. Premenstrual syndrome: beneficial effects of periodic, low-dose danazol. *Obstet Gynecol* 1987;70:33-6.
 95. O'Brien PM, Abukhalil IE. Randomized controlled trial of the management of premenstrual syndrome and premenstrual mastalgia using luteal phase only danazol. *Am J Obstet Gynecol* 1999;180:18-23.
 96. Graham CA, Sherwin BB. A prospective treatment study of premenstrual symptoms using a triphasic oral contraceptive. *J Psychosom Res* 1992;36:257-66.
 97. Goldstein BJ, Goodnick PJ. Selective serotonin reuptake inhibitors in the treatment of affective disorders. III. Tolerability, safety and pharmacoeconomics. *J Psychopharmacol* 1998;12:S55-87.
 98. Steiner M, Lamont J, Steinberg S, Stewart D, Reid R, Streiner D. Effect of fluoxetine on menstrual cycle length in women with premenstrual dysphoria. *Obstet Gynecol* 1997;90:590-5.
 99. Rosen RC, Lane RM, Menza M. Effects of SSRIs on sexual function: a critical review. *J Clin Psychopharmacol* 1999;19:67-85.
 100. Chambers CD, Johnson KA, Dick LM, Felix RJ, Jones KL. Birth outcomes in pregnant women taking fluoxetine. *N Engl J Med* 1996;335:1010-5.
 101. Nulman I, Rovet J, Stewart DE, Wolpin J, Gardner HA, Theis JG, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. *N Engl J Med* 1997;336:258-62.
 102. Pastuszak A, Schick-Boschetto B, Zuber C, Feldkamp M, Pinelli M, Sihn S. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). *JAMA* 1993;269:2246-8.
 103. Kulin NA, Pastuszak A, Sage SR, Schick-Boschetto B, Spivey G, Feldkamp M, et al. Pregnancy outcomes following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicentre study. *JAMA* 1998;279:609-10.
 104. Goldstein D, Sundell K. A review of the safety of selective serotonin reuptake inhibitors. *Hum Psychopharmacol* 1999;14:319-24.
 105. Eriksson E. Serotonin reuptake inhibitors for the treatment of premenstrual dysphoria. *Int Clin Psychopharmacol* 1999;14:S27-S33.
 106. Endicott J, Amsterdam J, Eriksson E, Frank E, Freeman E, Hirschfeld R, et al. Is premenstrual dysphoric disorder a distinct clinical entity? *J Womens Health Gender Based Med* 1999;8:663-79.
 107. Steiner M, Born L. Advances in the diagnosis and treatment of premenstrual dysphoria. *Cent Nerv Syst Drugs* 2000; 13:286-304.

**CANADIAN COLLEGE OF
NEUROPSYCHOPHARMACOLOGY**

**COLLÈGE CANADIEN DE
NEUROPSYCHOPHARMACOLOGIE**

CCNP Medal

This Award was established to honour individuals for a meritorious career in, and outstanding contribution to, neuropsychopharmacology in Canada as evidenced by their activities in education, administration and/or patient care. Achievement in research is not a necessary criterion for this Award.

The Award, which does not have to be awarded each year, consists of a bronze medal engraved with the name of the recipient.

Nomination for 2001 CCNP Medal

The names of nominees should be received by Dr. Andrew Greenshaw by November 30th, 2000. Supporting documentation must be received by December 31st, 2000. For each award, this documentation shall consist of:

1. Six copies of a two-page summary prepared by the sponsor describing the nominee's work and its importance in furthering the field of neuropsychopharmacology.
2. Six copies of the nominee's curriculum vitae and list of publications.
3. Six copies of a brief biographical sketch of the candidate prepared by the sponsor.

Formal presentation of the Award will be made to the recipient during the Annual Meeting of the College.

Please send the name of the nominee and a short supporting letter to:

Dr. Andrew J. Greenshaw
President - CCNP
University of Alberta, Department of Psychiatry
1E1.01 Walter MacKenzie Centre
8440-112 St.
Edmonton AB T6G 2B7

Deadline for receipt of initial nomination and short supporting letter is November 30, 2000.